Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Share-based Compensation: 2017-2024

Historic Share-based Compensation for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $113.9 million.

  • BridgeBio Pharma's Share-based Compensation rose 16.68% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.6 million, marking a year-over-year increase of 27.94%. This contributed to the annual value of $113.9 million for FY2024, which is 1.00% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Share-based Compensation of $113.9 million as of FY2024, which was down 1.00% from $115.0 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Share-based Compensation high stood at $115.0 million for FY2023, and its period low was $58.5 million during FY2020.
  • Over the past 3 years, BridgeBio Pharma's median Share-based Compensation value was $113.9 million (recorded in 2024), while the average stood at $107.6 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Share-based Compensation soared by 173.51% in 2020, and later decreased by 11.13% in 2022.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Share-based Compensation stood at $58.5 million in 2020, then skyrocketed by 80.59% to $105.6 million in 2021, then dropped by 11.13% to $93.8 million in 2022, then increased by 22.58% to $115.0 million in 2023, then dropped by 1.00% to $113.9 million in 2024.